@article{3931b5c9a9db44adbb2b6b822acb7947,
title = "Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15–16, 2020",
keywords = "Adoptive immunotherapy, Cancer vaccines, Checkpoint blockade agents, Immunotherapy, NIBIT, Targeted therapies",
author = "Matteo Bellone and Arianna Brevi and Vincenzo Bronte and Silvia Dusi and Ferrucci, {Pier Francesco} and Paola Nistic{\`o} and Antonio Rosato and Vincenzo Russo and Antonio Sica and Gabriele Toietta and Colombo, {Mario Paolo}",
note = "Funding Information: This meeting was supported in part by unrestricted grants from AstraZeneca, Becton Dikinson (BD), Bristol Meyers Squibb, Diatech Labline, Fuidigm, Incyte, Merck Sharp and Dome (MSD), Milteny Biotech, Nano String, Novartis, Pierre Fabre Oncology, Promega, and under the auspices of the AIOM, the Associazione Italiana Oncologia Toracica (AIOT), the Fondazione Associazione Italiana per la Ricerca sul Cancro (AIRC), the ACC, the Fondazione Melanoma onlus, the Fondazione Grazia Focacci, the Istituto Oncologico Veneto (IOV), the Fondazione Pezcoller, the SIC, the SIICA, and the Women for Oncology Italy. Funding Information: This meeting was organized in collaboration with the NIBIT Board of Directors.",
year = "2022",
month = jul,
doi = "10.1007/s00262-022-03145-0",
language = "English",
volume = "71",
pages = "1787--1794",
journal = "Cancer Immunology, Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "7",
}
